Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21
- 1 April 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (4), e28188
- https://doi.org/10.1002/pbc.28188
Abstract
Background Transient abnormal myelopoiesis (TAM) is a unique myeloproliferative disorder that occurs in neonates with constitutional trisomy 21/Down syndrome (DS). Although TAM also develops in neonates without constitutional trisomy 21, the clinical, cytogenetic, and molecular characteristics of those patients are not fully understood. Procedure We retrospectively evaluated the clinical and cytogenetic findings and GATA1 mutation status of 17 neonates with TAM and nonconstitutional trisomy 21 tested for GATA1 mutations at our institute, and compared the findings with those of 64 neonates with TAM and constitutional trisomy 21/DS. Results DS clinical features were observed in five of the 17 (29%) patients. In all patients, both trisomy 21 and GATA1 mutations were detected in diagnostic samples. Over a median follow-up of 33 (range, 0-139) months, early death (< 6 months of age) occurred in four patients (24%). Overall and event-free survivals were not significantly different between the patients with TAM and nonconstitutional trisomy 21 and those with TAM and constitutional trisomy 21/DS (five-year overall survival: 76% +/- 10% vs 53% +/- 13%, P = 0.40; five-year event-free survival: 55% +/- 13% vs 48% +/- 12%, P = 0.90). The five-year cumulative incidence of progression to myeloid leukemia of DS was also similar between the groups (21% vs 24%, P = 0.80). Conclusions Patients with TAM and nonconstitutional trisomy 21 exhibited similar biology and outcomes to those with TAM and constitutional trisomy 21/DS. The possibility of TAM should be considered even in phenotypically normal neonates with TAM symptoms, for appropriate management.Funding Information
- Japan Society for the Promotion of Science (JP26253061, JP18H04039, JP18K07810)
- Japan Agency for Medical Research and Development (JP18cm0106407)
This publication has 26 references indexed in Scilit:
- Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971Blood, 2011
- Transient Myeloproliferative Disorder in Neonates With and Without Down SyndromeJournal of Pediatric Hematology/Oncology, 2008
- Treatment and prognostic impact of transient leukemia in neonates with Down syndromeBlood, 2008
- Incidence and clinical implications of GATA1 mutations in newborns with Down syndromeBlood, 2007
- Hematological abnormalities during the first week of life among neonates with Down syndrome: Data from a multihospital healthcare systemAmerican Journal of Medical Genetics Part A, 2006
- Transient Neonatal Myeloproliferative Disorder Without Down Syndrome and Detection of GATA1 MutationJournal of Pediatric Hematology/Oncology, 2005
- Tetrasomy 21 transient leukemia with aGATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: Case report and review of the literaturePediatric Blood & Cancer, 2004
- Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndromeBlood, 2003
- Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesisBlood, 2003
- Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21Blood, 2003